China Medical System Holdings Ltd. engages in the production, marketing, promotion, and sale of drugs. The company employs 6,095 full-time employees The company went IPO on 2010-09-28. The firm's products include Plendil, Ursofalk, Augentropfen Stulln Mono Eye Drops, Hirudoid, Atopic Piel Series and Vmonalisa, among others. Its major marketed products cover the cardio-cerebrovascular, gastroenterology, ophthalmology, dermatology and medical aesthetic fields. The firm distributes its products within domestic market and to overseas markets.
根据最新的财务报表(Form-10K),China Medical System Holdings Limited 的总资产为 $19,198,净利润为 $1,488
CHSYF 的关键财务比率是什么?
China Medical System Holdings Limited 的流动比率是 10.64,净利 margin 为 18.11,每股销售为 $3.39。
China Medical System Holdings Limited 的收入按细分市场或地理位置如何划分?
China Medical System Holdings Limited 最大收入来源是 Pharmaceutical Products,在最近的收益报告中收入为 8,854,663,686。就地区而言, China 是 China Medical System Holdings Limited 的主要市场,收入为 8,854,663,686。
China Medical System Holdings Limited 是否盈利?
是的,根据最新的财务报表,China Medical System Holdings Limited 的净利润为 $1,488
China Medical System Holdings Limited 有负债吗?
是的,China Medical System Holdings Limited 的负债为 1,803
China Medical System Holdings Limited 的流通股有多少?
China Medical System Holdings Limited 的总流通股为 2,439.52